AngioDynamics Inc logo

AngioDynamics Inc(ANGO)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$11.87
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ANGO

11/13/2026: ANGO (1-star) is currently NOT-A-BUY. Pass it for now.

AngioDynamics Inc is a small-cap medical technology company specializing in minimally invasive devices for vascular interventions and cancer treatments. Its primary business strengths include robust double-digit sales growth in advanced Med Tech platforms like Auryon and AlphaVac, supported by active clinical trial validation. The core investment opportunity centers on scaling these differentiated proprietary technologies into large global markets while expanding insurance reimbursement coverage. However, key risks include ongoing bottom-line net losses, intense competition from well-capitalized medtech conglomerates, and execution pressures. The stock is best suited for growth-oriented investors willing to tolerate small-cap volatility while monitoring profitability progress and clinical trial milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile its Med Tech segment exhibits robust double-digit growth, overall company profitability remains under pressure.
Momentum investorStrong fit while signal remains positiveStrong quarter-over-quarter revenue growth in core technology lines can attract positive short-term market momentum when technical trends are favorable.
Value investorWeak fitThe lack of positive GAAP earnings makes traditional valuation metrics less applicable for value-oriented strategies.
Dividend investorWeak fitThe company does not pay dividends, directing all earnings and cash toward business reinvestment.
Low-risk investorWeak fitSmall-cap medical technology volatility and ongoing net losses present higher risk profiles unsuited for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighSmall-cap medical technology stocks frequently experience sharp price movements based on clinical trial updates and earnings reports.
Valuation riskMedium / highValuations are sensitive to execution milestones given the current absence of consistent GAAP profitability.
Competition risk (large medtech conglomerates)HighCompeting against well-resourced giants like Boston Scientific and Medtronic threatens long-term market share gains.
Business qualityMediumProprietary medical devices offer strong gross margins, but bottom-line profitability remains constrained by high R&D and SG&A expenses.
Dividend incomeLow / noneIncome-focused investors receive zero yield since no cash dividends are distributed.
Execution riskHighSuccessful scaling of newer platforms like Auryon and AlphaVac is critical to achieving sustained financial turnaround.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 499.19M USD
Price to earnings Ratio -
1Y Target Price 19.75
Price to earnings Ratio -
1Y Target Price 19.75
Volume (30-day avg) 865.5K shares
Beta 0.28
52 Weeks Range 9.39 - 16.29
Updated Date 11/15/2026
52 Weeks Range 9.39 - 16.29
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.78

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Instruments & Supplies

BUY participation
60.0%
Active BUY / eligible
3 / 5
30-Day BUY Count Change
+1

Eligible universe: 5 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -6.31%
Avg. Invested days 42
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ANGO receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
ANGO has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and strong ownership. In FY2026 versus FY2025, growth and ownership metrics are mixed: negative earnings growth (-8.1%), soft cash generation (FCF margin 0.2%), moderate revenue growth (+9.5%).

Financial Health Rating

★★★★★
ANGO's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 33.2%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is ANGO's strongest growth driver at +103.5% FY2026 versus FY2025 (strong, 5 stars). By comparison, while revenue growth (+9.5%, moderate) and earnings growth (-8.1%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 91.8% and approximately 77.9% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 13.68% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 9.04%
Point72 Asset Management, L.P. 7.28%
Systematic Financial Management LP 6.28%
Armistice Capital, LLC 5.23%
Royce & Associates, LP 4.68%

Unit Economics (Per $1K Revenue)

★★★★★
ANGO generates approximately $546 of gross profit, $-125 of operating income, and $2 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Operating losses explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -1.22% (Tax Credit)

Quantitative Style Profile

★★★★★
ANGO has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Med Tech SegmentRevenues derived from advanced high-growth platforms including the Auryon atherectomy system and AlphaVac/AngioVac thrombectomy systems.This is the primary growth engine driving double-digit percentage sales increases for the company.
Med Device SegmentRevenues from established product portfolios including peripheral vascular tools, vascular access ports, drainage catheters, and ablation systems.Provides a steady base of recurring clinical product sales while higher-margin technologies scale up.
Geographic OperationsDirect and distributor-based sales generated primarily within the United States alongside international markets.The vast majority of revenue originates domestically in the US healthcare market.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE 96.15
Enterprise Value 459.43M
Price to Sales(TTM) 1.53
Enterprise Value 459.43M
Price to Sales(TTM) 1.53
Enterprise Value to Revenue 1.41
Enterprise Value to EBITDA 120.9
Shares Outstanding 42.05M
Shares Floating 32.76M
Shares Outstanding 42.05M
Shares Floating 32.76M
Percent Insiders 13.68
Percent Institutions 91.75

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.